CN110583956A - Double-histidine antibacterial agent, preparation method and application - Google Patents
Double-histidine antibacterial agent, preparation method and application Download PDFInfo
- Publication number
- CN110583956A CN110583956A CN201910812009.5A CN201910812009A CN110583956A CN 110583956 A CN110583956 A CN 110583956A CN 201910812009 A CN201910812009 A CN 201910812009A CN 110583956 A CN110583956 A CN 110583956A
- Authority
- CN
- China
- Prior art keywords
- histidine
- modified
- double
- cold plasma
- antibacterial agent
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000003242 anti bacterial agent Substances 0.000 title claims abstract description 20
- 238000002360 preparation method Methods 0.000 title abstract description 12
- 230000005495 cold plasma Effects 0.000 claims abstract description 31
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims abstract description 12
- 229910052757 nitrogen Inorganic materials 0.000 claims abstract description 6
- 239000007787 solid Substances 0.000 claims abstract description 5
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims description 11
- 239000004599 antimicrobial Substances 0.000 claims description 7
- 238000000034 method Methods 0.000 claims description 7
- 150000001413 amino acids Chemical class 0.000 claims description 5
- 239000012153 distilled water Substances 0.000 claims description 5
- 239000007789 gas Substances 0.000 claims description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 5
- 230000000813 microbial effect Effects 0.000 claims description 2
- 238000003756 stirring Methods 0.000 claims description 2
- 230000000844 anti-bacterial effect Effects 0.000 abstract description 16
- 230000000694 effects Effects 0.000 abstract description 7
- 235000013305 food Nutrition 0.000 abstract description 6
- 238000000338 in vitro Methods 0.000 abstract description 5
- 241000208822 Lactuca Species 0.000 abstract 1
- 235000003228 Lactuca sativa Nutrition 0.000 abstract 1
- 230000003115 biocidal effect Effects 0.000 abstract 1
- 239000002778 food additive Substances 0.000 abstract 1
- 235000013373 food additive Nutrition 0.000 abstract 1
- 235000014304 histidine Nutrition 0.000 description 9
- 241000894006 Bacteria Species 0.000 description 8
- 241000191967 Staphylococcus aureus Species 0.000 description 8
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 8
- 239000002245 particle Substances 0.000 description 6
- 239000000243 solution Substances 0.000 description 6
- 230000001954 sterilising effect Effects 0.000 description 6
- 238000004659 sterilization and disinfection Methods 0.000 description 6
- 230000000845 anti-microbial effect Effects 0.000 description 5
- 239000000463 material Substances 0.000 description 4
- 238000009832 plasma treatment Methods 0.000 description 4
- 239000000725 suspension Substances 0.000 description 4
- 230000003698 anagen phase Effects 0.000 description 3
- 230000004071 biological effect Effects 0.000 description 3
- 239000006059 cover glass Substances 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 238000010998 test method Methods 0.000 description 3
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 230000005672 electromagnetic field Effects 0.000 description 2
- 150000004676 glycans Chemical class 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- 238000009630 liquid culture Methods 0.000 description 2
- 235000015097 nutrients Nutrition 0.000 description 2
- 239000008055 phosphate buffer solution Substances 0.000 description 2
- 229920001282 polysaccharide Polymers 0.000 description 2
- 239000005017 polysaccharide Substances 0.000 description 2
- 230000002000 scavenging effect Effects 0.000 description 2
- SGCGMORCWLEJNZ-UWVGGRQHSA-N His-His Chemical compound C([C@H]([NH3+])C(=O)N[C@@H](CC=1NC=NC=1)C([O-])=O)C1=CN=CN1 SGCGMORCWLEJNZ-UWVGGRQHSA-N 0.000 description 1
- 240000004201 Lactuca sativa var. crispa Species 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- 238000009833 condensation Methods 0.000 description 1
- 230000005494 condensation Effects 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 230000018044 dehydration Effects 0.000 description 1
- 238000006297 dehydration reaction Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 208000028659 discharge Diseases 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 150000002411 histidines Chemical class 0.000 description 1
- 108010028295 histidylhistidine Proteins 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 229910044991 metal oxide Inorganic materials 0.000 description 1
- 150000004706 metal oxides Chemical class 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 239000002086 nanomaterial Substances 0.000 description 1
- 239000002073 nanorod Substances 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 239000011941 photocatalyst Substances 0.000 description 1
- 238000001338 self-assembly Methods 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 238000004381 surface treatment Methods 0.000 description 1
- 238000001132 ultrasonic dispersion Methods 0.000 description 1
- 238000009827 uniform distribution Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L3/00—Preservation of foods or foodstuffs, in general, e.g. pasteurising, sterilising, specially adapted for foods or foodstuffs
- A23L3/34—Preservation of foods or foodstuffs, in general, e.g. pasteurising, sterilising, specially adapted for foods or foodstuffs by treatment with chemicals
- A23L3/3454—Preservation of foods or foodstuffs, in general, e.g. pasteurising, sterilising, specially adapted for foods or foodstuffs by treatment with chemicals in the form of liquids or solids
- A23L3/3463—Organic compounds; Microorganisms; Enzymes
- A23L3/3526—Organic compounds containing nitrogen
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Microbiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Nutrition Science (AREA)
- Engineering & Computer Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
Abstract
The invention belongs to the field of food safety, and particularly relates to a preparation method and application of a cold plasma modified bi-histidine antibacterial agent. According to the invention, solid double-histidine is exposed to nitrogen plasma, and the cold plasma is utilized to bombard the surface of the double-histidine, so as to obtain the cold plasma modified double-histidine. Compared with unmodified bishistidine, the cold plasma modified bishistidine has obviously improved antibacterial activity. It has raised activity in vitro antibiotic and biomembrane resisting effect and obvious biomembrane eliminating effect on lettuce surface. The application of the food additive in the food field is expanded.
Description
Technical Field
The invention belongs to the field of food safety, and particularly relates to a cold plasma modified bi-histidine antibacterial agent, and a preparation method and application thereof.
Background
With the improvement of living standard and the progress of technology, people pay more and more attention to food sanitation and safety, which promotes the development of antibacterial agents. The antibacterial agent which is safe, nontoxic and high in antibacterial efficiency is favored by people.
The bi-histidine (His-His, HH) belongs to a novel biological self-assembly material and is an important element for preparing biological functional nano materials. It is formed by dehydration condensation of two histidines, the structure comprises two benzene rings, one end is-NH2One end of the derivative is-COOH which exists in a zwitterionic form at the isoelectric point, so that the derivative has great potential utilization value.
Plasma (plasma) is a fourth species existing form other than solid, liquid and gas, and is a conductive fluid composed of electrons, ions, radicals and neutral particles, and maintains electric neutrality as a whole. The plasma can be obtained by destroying the molecular structure into atoms by continuously heating the gas, applying a strong electromagnetic field and the like, and ionizing. The gas temperature of the low-temperature plasma is relatively low, and the generated plasma has high density, uniform distribution, convenient utilization and good controllability. The low-temperature plasma is generated after various physical and chemical reactions occur in the generation process: electromagnetic fields, heat, ultraviolet light, charged particles, excited particles, metastable particles, and the like. These active components contain a high enough energy potential to break chemical bonds, which can initiate a series of physicochemical reactions to modify the properties of the substance. CN109569684A discloses a plasma modified metal oxide and g-carbon nitride co-modified titanium dioxide nanorod composite photocatalyst, and a preparation method and an application thereof. CN108409887A discloses a preparation method of antibacterial polysaccharide, which is to carry out atmospheric pressure plasma jet discharge treatment on polysaccharide solution. The above patents all utilize plasma to improve the biological activity of the substance.
The invention utilizes the cold plasma technology to modify the properties of the bi-histidine, and aims to improve the biological activity of the bi-histidine, improve the antibacterial ability of the bi-histidine and expand the application of the bi-histidine in the food industry.
Disclosure of Invention
The invention aims to provide a cold plasma modified bi-histidine antibacterial agent, a preparation method and application thereof in the field of food safety.
The preparation method of the invention comprises the steps of firstly treating solid bi-histidine with cold plasma, and then preparing a modified bi-histidine solution to obtain the modified bi-histidine antibacterial agent.
The cold plasma treatment is performed by using nitrogen as an exciting gas, the flow rate of the nitrogen is 100sccm, the treatment time of the cold plasma is 3-5 min, and the treatment power is 300-500W.
The preparation method of the modified bi-histidine solution comprises the following steps: dissolving the modified bi-histidine into ether to fully dissolve the modified bi-histidine, and then adding distilled water.
The method for dissolving and modifying the bi-histidine by using the diethyl ether is to stir the bi-histidine on a magnetic stirrer at the room temperature of 200rpm for 1 min.
The concentration of the modified double-histidine solution is 5-10mg/mL after distilled water is added.
The preparation cost of the bi-histidine is high, so that the property of the bi-histidine is modified by utilizing charged particles, excited particles and the like generated in the generation process of the low-temperature plasma, so that the biological activity and the antibacterial activity of the bi-histidine are improved. The modified bi-histidine obtained by the invention saves cost and can obtain better antibacterial activity.
Drawings
Figure 1 antimicrobial effect of cold plasma modified two-histidine antimicrobial on free staphylococcus aureus (s.
Figure 2 antibacterial effect of cold plasma modified two-histidine antimicrobial on s.
Figure 3 clearance of cold plasma modified bis-histidine antimicrobial on s.
Figure 4 scavenging effect of cold plasma modified two-component amino acid antibacterial agent on s.
Detailed Description
The following examples illustrate specific embodiments of the present invention, but the scope of the present invention is not limited thereto.
Example 1 preparation of cold plasma modified bis-histidine antimicrobial agent
1. Test materials and apparatus
2. Test method
The preparation method of the cold plasma modified double-histidine antibacterial agent comprises the following steps:
1) placing the small beaker tube filled with the double-component solid ammonia acid in a cold plasma surface treatment instrument, wherein the nitrogen flow is 100sccm, and treating for 3-5 min by using 300-500W cold plasma.
2) After adding ether, the mixture was stirred for 1min at room temperature on a magnetic stirrer at a rotation speed of 200 rpm.
3) Adding distilled water to make the concentration of the modified double-histidine solution be 5-10mg/mL, thus obtaining the modified double-histidine antibacterial agent.
Example 2 cold plasma modified bis-histidine antimicrobial agent antimicrobial effect on s
1. Test materials and apparatus
2. Test method
1) Antibacterial effect of cold plasma modified bis-histidine antibacterial agent on S.aureus in vitro
Aureus is inoculated in a nutrient broth liquid culture medium and cultured for 24 hours at 37 ℃ with shaking (150rpm) to obtain staphylococcus aureus in logarithmic growth phase.
② adding S.aureus of logarithmic growth phase into sterile phosphate buffer solution, and diluting to 10 degree of gradient4-105CFU/mL, then add antibacterial agent (two histidine, modified two histidine), make it the final concentration of 3.3 mg/mL.
③ culturing the bacterial suspension added with the antibacterial agent at 37 ℃ for 24h, and then measuring the number of the residual bacteria by using a plate counting method. Unmodified bishistidine was added as a control and suspension of s.
2) Antibacterial effect of plasma modified double-histidine antibacterial agent on S.aureus biomembrane in vitro
Aureus is inoculated in a nutrient broth liquid culture medium and cultured for 48 hours at 37 ℃ under shaking (150rpm) to obtain staphylococcus aureus in logarithmic growth phase.
② adding 500. mu.L of S.aureus suspension (10) into a 24-well plate8CFU/mL), 5mL of TSB medium was added to each well, and a sterile cover slip (2 cm. times.2 cm) was added thereto, followed by incubation at 37 ℃ for 2 days.
Thirdly, the cover glass is washed by sterile phosphate buffer solution to remove free bacteria, and antibacterial agent (double-histidine and modified double-histidine) is added to lead the final concentration to be 6.6mg/mL and the treatment is carried out for 24 h.
Taking out a cover glass, putting the cover glass into a centrifuge tube, adding 10mL of sterile phosphate buffer, performing ultrasonic dispersion for 30min to obtain free bacteria, and measuring the number of the residual bacteria by using a plate counting method. Unmodified bishistidine was added as a control and s.
3. Test results
1) Antibacterial effect of cold plasma modified bis-histidine antibacterial agent on S.aureus in vitro
As shown in fig. 1, the residual bacteria numbers of the control group and the modified two-histidine group were significantly reduced, and the sterilization effect of the modified two-histidine group was more significant, compared to the blank group. After the double histidine with 3.3mg/mL acts for 24 hours, the staphylococcus aureus is reduced from 5.462log CFU/mL to 3.104log CFU/mL, the sterilization rate reaches 99.56, while the staphylococcus aureus is reduced to 1.065log CFU/mL after the double histidine with cold plasma modification acts, the sterilization rate reaches 99.99%, and the result shows that the antibacterial effect of the double histidine with cold plasma treatment is enhanced.
2) Antibacterial effect of plasma modified double-histidine antibacterial agent on S.aureus biomembrane in vitro
As shown in fig. 2, the control group and the modified bishistidine group both exhibited good biofilm removal effects, and the modified bishistidine group had significant removal effects, compared to the blank group. After the action of the double-histidine for 24 hours, the removal rate of the S.aureus biomembrane reaches 95.80%, and after the action of the cold plasma modified double-histidine, the removal rate of the S.aureus biomembrane reaches 99.94%, and the result shows that the antibacterial effect of the double-histidine after the cold plasma treatment is enhanced and is consistent with the previous result.
Example 3 Cold plasma modified bis-histidine antimicrobial Agents scavenging action on s
1. Test materials
2. Test method
Cutting lettuce into 1 × 1cm2The sample of (1). To reduce the natural microbial community, the samples were treated with uv light for 30 min.
② inoculation of the sample into a Staphylococcus aureus suspension (10)3-4CFU/mL) for 1h to attach bacteria, then the samples were dried and incubated at 25 ℃ for 48 h.
③ immersing the sample in a 10mg/mL modified bishistidine solution and incubating the sample at 4 ℃ or 25 ℃.
After 0,1,2 and 3d, respectively, each set of samples was transferred to a sterile homogenizer bag, which was supplemented with 10mL PBS and homogenized for 5min using a homogenizer. Subsequently, the number of bacteria was counted using plate colony counts. Unmodified bishistidine was added as a control and s.
3. Test results
As shown in FIG. 3, the colony count increased to 10 after 3d in the blank at 4 ℃7CFU/mL, the residual bacteria number of the control group and the modified double-histidine group are obviously reduced, and the sterilization effect of the modified double-histidine group is more obvious. After 10mg/mL of double histidine acts for 3 days, the sterilization rate of staphylococcus aureus is reduced from 6.375log CFU/mL to 4.86log CFU/mL, and reaches 96.95%, while after the cold plasma modified double histidine acts, the sterilization rate of staphylococcus aureus is reduced to 3.246log CFU/mL, and reaches 99.93%, and the result shows that the antibacterial effect of the double histidine is enhanced after the cold plasma treatment. As shown in FIG. 4, at 25 ℃ the colony count of blank group rapidly increased to 10 after 1d8CFU/mL, while the control and modified bishistidine groups showed similar bactericidal effect as 4 ℃. Therefore, the modified bi-histidine has more excellent antibacterial activity.
Claims (5)
1. The double-histidine antibacterial agent is characterized by being prepared by the following steps: the method comprises the steps of bombarding solid double-component amino acid by using cold plasma, improving the bioactivity of the double-component amino acid, preparing a modified double-component amino acid solution, and obtaining a plasma modified double-component amino acid antibacterial agent for dealing with microbial pollution.
2. The bi-histidine antimicrobial agent of claim 1, wherein: the cold plasma takes nitrogen as exciting gas, the flow of the nitrogen is 100sccm, the treatment time of the cold plasma is 3-5 min, and the treatment power is 300-500W.
3. The bi-histidine antimicrobial agent according to claim 1, wherein the modified bi-histidine solution is prepared by a method comprising: dissolving the modified bi-histidine in ether to fully dissolve the modified bi-histidine, and then adding sterile distilled water to prepare the required modified bi-histidine solution.
4. A bi-histidine antimicrobial agent as claimed in claim 3, wherein: the modified bi-histidine is dissolved in ether and then placed on a magnetic stirrer to stir at the room temperature for 1min at the rotation speed of 200 rpm.
5. A bi-histidine antimicrobial agent as claimed in claim 3, wherein: the concentration of the modified double-histidine solution is 5-10mg/mL after sterile distilled water is added.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201910812009.5A CN110583956A (en) | 2019-08-30 | 2019-08-30 | Double-histidine antibacterial agent, preparation method and application |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201910812009.5A CN110583956A (en) | 2019-08-30 | 2019-08-30 | Double-histidine antibacterial agent, preparation method and application |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN110583956A true CN110583956A (en) | 2019-12-20 |
Family
ID=68856832
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201910812009.5A Pending CN110583956A (en) | 2019-08-30 | 2019-08-30 | Double-histidine antibacterial agent, preparation method and application |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN110583956A (en) |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH08151326A (en) * | 1994-11-28 | 1996-06-11 | Sunstar Inc | Antimicrobial preparation |
| CN1763081A (en) * | 2005-09-16 | 2006-04-26 | 中山大学 | Antibiotic dipeptide and its chemical modifier, its preparation method and uses |
| CN107114655A (en) * | 2017-04-19 | 2017-09-01 | 江苏大学 | A kind of g C of corona treatment3N4Antiseptic and preparation method and purposes |
| CN109122816A (en) * | 2018-08-21 | 2019-01-04 | 江苏大学 | A kind of preparation method and application of the black angle orchid extract of corona treatment |
-
2019
- 2019-08-30 CN CN201910812009.5A patent/CN110583956A/en active Pending
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH08151326A (en) * | 1994-11-28 | 1996-06-11 | Sunstar Inc | Antimicrobial preparation |
| CN1763081A (en) * | 2005-09-16 | 2006-04-26 | 中山大学 | Antibiotic dipeptide and its chemical modifier, its preparation method and uses |
| CN107114655A (en) * | 2017-04-19 | 2017-09-01 | 江苏大学 | A kind of g C of corona treatment3N4Antiseptic and preparation method and purposes |
| CN109122816A (en) * | 2018-08-21 | 2019-01-04 | 江苏大学 | A kind of preparation method and application of the black angle orchid extract of corona treatment |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Li et al. | Highly selective antibacterial activities of silver nanoparticles against Bacillus subtilis | |
| CN103408002B (en) | Microbial reduction of graphene oxide and preparation method for graphene | |
| CN108822838B (en) | Preparation method and application of copper-doped carbon quantum dots | |
| CN111803631B (en) | Preparation method and application of carbon nanodots with efficient antibacterial property | |
| CN115337448B (en) | Tannic acid coupled polyphosphazene-based hydrogel wound dressing with anti-inflammatory, antibacterial and ROS response performances and preparation method thereof | |
| CN108865940B (en) | Heterotrophic nitrification-aerobic denitrification bacillus and composite bacterial preparation thereof | |
| CN110591948A (en) | Compound microbial agent for degrading quinolone antibiotics and preparation method and application thereof | |
| CN112471173A (en) | Preparation method of graphene antibacterial composite membrane and prepared antibacterial composite membrane | |
| CN112870431B (en) | Antibacterial hydrogel with G-quadruplex structure used as cascade reactor and preparation method and application thereof | |
| R El Shanshoury et al. | Extracellular biosynthesis of silver nanoparticles using aquatic bacterial isolate and its antibacterial and antioxidant potentials | |
| CN110583956A (en) | Double-histidine antibacterial agent, preparation method and application | |
| CN115838770B (en) | Method for preparing biological nano-selenium by using bacillus sp HZ3 | |
| CN114469893B (en) | Quaternary ammonium salt silicon dioxide nano-particles, preparation method and application | |
| CN110592068A (en) | Compound preparation for in-situ resolution of soil macrolide antibiotic pollution and preparation method and application thereof | |
| CN113755400B (en) | Bacillus cereus for degrading aureomycin and application thereof | |
| CN107022504B (en) | Lactic acid bacteria with formaldehyde degradation effect and application thereof | |
| Popuri et al. | Evaluation of antibacterial activity and characterization of synthesized biodegradable copolymers | |
| CN113229292B (en) | Cu/C composite nanosheet material and preparation method and application thereof | |
| CN115806478B (en) | Metal salt of hinokitiol, and preparation method and application thereof | |
| CN117431062B (en) | Preparation method and application of green luminous amino acid derivative antibacterial carbon dot | |
| CN116212088B (en) | Rare earth metal-based antibacterial bandage and preparation method thereof | |
| CN106719816A (en) | Yittrium oxide stalk cellulose composite Nano antibacterial material | |
| CN112826002B (en) | Nisin compound and application thereof in preparation of antibacterial agent | |
| CN107585973B (en) | Method for efficiently removing Cr (VI) in wastewater solution | |
| CN112980255A (en) | Antibacterial coating and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20191220 |
|
| RJ01 | Rejection of invention patent application after publication |